<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114321</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0070</org_study_id>
    <nct_id>NCT01114321</nct_id>
  </id_info>
  <brief_title>Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease</brief_title>
  <official_title>Glucose Tolerance in Patients With an Idiopathic Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Dysfunction of autonomic nervous system is an important non motor feature of Parkinson'&#xD;
      disease (PD). Lewy body formation is widely distributed in hypothalamus and in sympathetic&#xD;
      and parasympathetic systems. Animal studies suggest a link between hypothalamus sensing of&#xD;
      substrates and glucose metabolism. Thus, hypothalamus lesions could lead to change in glucose&#xD;
      metabolism. Recently, we showed that fasting blood glucose level was significantly higher in&#xD;
      PD patients than in control group suggesting that glucose tolerance may be impaired in PD.&#xD;
      Some studies provided evidence for higher diabetes prevalence in PD patients whereas others&#xD;
      showed no difference or a reduced risk of diabetes prevalence in PD patients compared to&#xD;
      healthy subjects.&#xD;
&#xD;
      So, the risk that a PD patient develops a glucose intolerance or a diabetes is not clearly&#xD;
      established and merit to be studied considering the damageable consequences for patient&#xD;
      healthy.&#xD;
&#xD;
      The aim of this prospective study was to determine the risk that a PD patient develop a&#xD;
      glucose intolerance or a diabetes compared to a matched control group, using an oral glucose&#xD;
      tolerance test (OGTT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 patients&#xD;
&#xD;
      Inclusion visit :&#xD;
&#xD;
        -  Clinical examination/ Interview on health and medical history&#xD;
&#xD;
        -  Complete UPDRS, MMS&#xD;
&#xD;
        -  Biologic check up&#xD;
&#xD;
      Protocol :&#xD;
&#xD;
      All patients were studied in the postabsorptive state after a 10-h overnight fast.&#xD;
&#xD;
      On the day of the experiment, patients did not receive their treatment. One catheter was&#xD;
      inserted for blood sample collections. Patients ingested then 75 g of glucose.&#xD;
&#xD;
      Blood samples were collected for plasma glucose and plasma insulin concentration analyses at&#xD;
      T0, T30, T60, T90, T120, T150 and T180. Urinary glucose was researched at T0 and T120.&#xD;
&#xD;
      In parallel, a dysautonomia evaluation of each patient was made (SCOPA AUT questionnaire,&#xD;
      Tilt test).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the plasma glucose concentration measured 120 min after the oral glucose surcharge intake.</measure>
    <time_frame>120 min after the oral glucose surcharge intake.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin concentration kinetic</measure>
    <time_frame>at T0, T30, T60, T90, T120, T150 and T180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration kinetic</measure>
    <time_frame>at T0, T30, T60, T90, T120, T150 and T180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose measurement</measure>
    <time_frame>at T0 and T120</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Protein and calorie controlled diet</intervention_name>
    <description>Protein and calorie controlled diet Self-hypnotic relaxation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age : 18-70 years&#xD;
&#xD;
          -  Patient with an idiopathic Parkinson's disease according to the criteria of the&#xD;
             &quot;Parkinson's Disease Society Brain Bank&quot; with a duration of disease &gt;5years&#xD;
&#xD;
          -  MMS&gt;24/30&#xD;
&#xD;
          -  No treatment modification 7 days before the inclusion&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
          -  Agreement of patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient treated with antibiotics, AINS, AIS or other treatment which could interfere&#xD;
             with the protocol&#xD;
&#xD;
          -  Patients with significant heart, respiratory, psychiatric, metabolic, hepatic, kidney&#xD;
             diseases; diabetes, heart deficiency, chronic kidney deficiency, untreated thyroid&#xD;
             disease â€¦&#xD;
&#xD;
          -  Patient treated with a deep brain stimulation&#xD;
&#xD;
          -  Patients with metabolic and/or biological anomalies&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Medical or chirurgical previous history which could interfere with the protocol&#xD;
&#xD;
          -  Alcohol (&gt;30g/day); Tobacco (&gt;10 cigarettes/day)&#xD;
&#xD;
          -  Participation to an other study at the same time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck DURIF, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>April 29, 2010</study_first_submitted>
  <study_first_submitted_qc>April 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patrick LACARIN</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Idiopathic Parkinson's disease</keyword>
  <keyword>Glucose intolerance</keyword>
  <keyword>Diabetes</keyword>
  <keyword>OGTT</keyword>
  <keyword>Patient with an Idiopathic Parkinson's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

